Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Consensus recommendations for the diagnosis and treatment of acquired hemophilia A

Collins, Peter William ORCID:, Baudo, Francesco, Huth-Kühne, Angela, Ingerslev, Jørgen, Kessler, Craig M., Castellano, Maria, Shima, Midori, St-Louis, Jean and Lévesque, Hervé 2010. Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Research Notes 3 , 161. 10.1186/1756-0500-3-161

[thumbnail of Collins 2010.pdf]
PDF - Published Version
Available under License Creative Commons Attribution.

Download (986kB) | Preview


Background Acquired hemophilia A (AHA) is a rare bleeding disorder caused by an autoantibody to coagulation factor (F) VIII. It is characterized by soft tissue bleeding in patients without a personal or family history of bleeding. Bleeding is variable, ranging from acute, life-threatening hemorrhage, with 9-22% mortality, to mild bleeding that requires no treatment. AHA usually presents to clinicians without prior experience of the disease, therefore diagnosis is frequently delayed and bleeds under treated. Methods Structured literature searches were used to support expert opinion in the development of recommendations for the management of patients with AHA. Results Immediate consultation with a hemophilia center experienced in the management of inhibitors is essential to ensure accurate diagnosis and appropriate treatment. The laboratory finding of prolonged activated partial thromboplastin time with normal prothrombin time is typical of AHA, and the diagnosis should be considered even in the absence of bleeding. The FVIII level and autoantibody titer are not reliable predictors of bleeding risk or response to treatment. Most patients with AHA are elderly; comorbidities and underlying conditions found in 50% of patients often influence the clinical picture. Initial treatment involves the control of acute bleeding with bypassing agents. Immunosuppressive treatment to eradicate the FVIII inhibitor should be started as soon as the diagnosis is confirmed to reduce the time the patient is at risk of bleeding. Conclusions These recommendations aim to increase awareness of this disorder among clinicians in a wide range of specialties and provide practical advice on diagnosis and treatment.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Systems Immunity Research Institute (SIURI)
Subjects: R Medicine > R Medicine (General)
Publisher: BioMed Central
ISSN: 1756-0500
Date of First Compliant Deposit: 30 March 2016
Last Modified: 05 May 2023 00:51

Citation Data

Cited 140 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item


Downloads per month over past year

View more statistics